Medivir AB (LTS:0GP7) Intangible Assets: kr66.50 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GP7 Medivir AB LTS:0GP7
44 GF Score
Price kr1.90
GF Value kr1.01
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Intangible Assets?

Medivir AB LTS:0GP7 +10.54% 44 Intangible Assets is kr66.50 Mil as of Jun. 2026. GuruFocus rates LTS:0GP7 with a GF Score™ of 44/100 and a GF Value™ of kr1.01 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Medivir AB's intangible assets for the quarter that ended in Jun. 2026 was kr66.50 Mil.


Medivir AB  (LTS:0GP7) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Medivir AB Intangible Assets Related Terms


Medivir AB Intangible Assets Historical Data

* Premium members only.

The historical data trend for Medivir AB's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Intangible Assets Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.31 96.31 96.31 96.31 66.49

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.30 96.30 66.49 66.50 66.50
LTS:0GP7
44GF Score
Medivir AB LTS:0GP7
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of kr66.50 Mil mean?
Medivir AB (LTS:0GP7) has a Intangible Assets of kr66.50 Mil as of Jun. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Medivir AB and its competitors.
Is Medivir AB's Intangible Assets too high?
Medivir AB's current Intangible Assets is kr66.50 Mil. Overall, Medivir AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Intangible Assets compare to VRTX and REGN?
Medivir AB's Intangible Assets of kr66.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Medivir AB and its competitors. Medivir AB's current Intangible Assets is kr66.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.01, compared to a current price of kr1.90 — trading 88.2% above its estimated fair value. The current Intangible Assets is kr66.50 Mil. Medivir AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Intangible Assets is kr66.50 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (LTS:0GP7) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.90 is trading 88.2% above its estimated GF Value™ of kr1.01. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for LTS:0GP7:

  • Intangible Assets: kr66.50 Mil
  • GF Value™: kr1.01 vs. price of kr1.90 (88.2% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
44GF Score

Get the complete analysis for LTS:0GP7

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.90
Price
kr1.01
GF Value